BNP Paribas Financial Markets Increases Stake in HealthEquity, Inc. (NASDAQ:HQY)

BNP Paribas Financial Markets lifted its stake in HealthEquity, Inc. (NASDAQ:HQY) by 165.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,437 shares of the company’s stock after buying an additional 12,745 shares during the quarter. BNP Paribas Financial Markets’ holdings in HealthEquity were worth $1,673,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mackenzie Financial Corp lifted its stake in HealthEquity by 16.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after purchasing an additional 325,906 shares in the last quarter. Generate Investment Management Ltd bought a new stake in shares of HealthEquity in the second quarter worth about $24,184,000. Vaughan Nelson Investment Management L.P. lifted its position in shares of HealthEquity by 36.7% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after buying an additional 226,563 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in HealthEquity by 924.2% during the second quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock valued at $18,983,000 after buying an additional 198,718 shares during the last quarter. Finally, Overbrook Management Corp purchased a new position in HealthEquity during the 2nd quarter valued at approximately $12,284,000. Institutional investors own 99.55% of the company’s stock.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares of the company’s stock, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the transaction, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,536 shares of company stock valued at $884,517 in the last quarter. 2.20% of the stock is owned by insiders.

HealthEquity Trading Down 0.6 %

HQY opened at $100.21 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The stock’s 50 day moving average price is $92.42 and its 200-day moving average price is $83.61. HealthEquity, Inc. has a one year low of $62.10 and a one year high of $105.82. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of 83.51, a P/E/G ratio of 1.61 and a beta of 0.55.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HQY. Bank of America increased their target price on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Mizuho initiated coverage on shares of HealthEquity in a research report on Wednesday. They set an “outperform” rating and a $126.00 price objective for the company. The Goldman Sachs Group began coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Barrington Research lifted their price target on HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $109.64.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.